ArticleJournal of lipid research2021
Nonalcoholic fatty liver disease stratification by liver lipidomics.
Article in Journal of lipid research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 81 citations in OpenAlex.
- Efficacy and serum metabolomic analysis of Jiu Wei Qingzhi Formula in treating non-alcoholic fatty liver disease: study protocol for a parallel-armed, randomized controlled trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- MetALD Molecular Signatures: What We Know, What We Lack, and How to Move Forward Through Integrated Multi-Omics.Metabolites · 2026Review
- A lipidomics roadmap: from basic research to societal challenges.Nature communications · 2026Review
- Histo-LCM-Hi-C Reveals 3D Chromatin Conformations of Spatially Localized Rare Cells in Tissues at High Resolution.Genomics, proteomics & bioinformatics · 2026Article
- Article
- Cross-organ multi-omics profiling of microbiome and metabolome along the gut-liver axis in MASH model mice induced by western diet and MC4R knockout.Gut pathogens · 2026Article
- Context-dependent Activities of Mitrephorone Link Lipid Redirection, Anti-inflammatory Action, and Ferroptosis Control to Hepatocyte Protection.Theranostics · 2026Article
- Article
- Gamma oryzanol modulates hepatic lipids expression and regulates integrated pathways in liver disease pathophysiology under a high sugar fat diet.Scientific reports · 2025Article
- Best practices and tools in R and Python for statistical processing and visualization of lipidomics and metabolomics data.Nature communications · 2025Review
- Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model.International journal of molecular sciences · 2025Article
- Sex-specific lipidomic signatures in aortic valve disease reflect differential fibro-calcific progression.Nature communications · 2025Article
- Review
- Sodium alginate supplementation can alleviate non-alcoholic fatty liver disease in rats by restoring hepatic lipid metabolism and gut microbiota.Current research in food science · 2025Article
- Mechanism of swertiamarin and novel nitrogen-containing metabolites (Frontiers in pharmacology · 2025Article
- A Comprehensive Analysis of Liver Lipidomics Signature in Adults with Metabolic Dysfunction-Associated Steatohepatitis-A Pilot Study.International journal of molecular sciences · 2024Article
- Unveiling functionality and conducting two-sample mendelian randomization on WGCNA-identified oxidative stress-related hub genes in metabolic dysfunction-associated fatty liver disease.Biochemistry and biophysics reports · 2024Article
- Effect of diet and genotype on the lipidome of mice with altered lipoprotein metabolism.iScience · 2024Article
- A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles.Acta pharmacologica Sinica · 2024Article
- Liver-specific mitochondrial amidoxime-reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models.Hepatology communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common metabolic dysfunction leading to hepatic steatosis. However, NAFLD's global impact on the liver lipidome is poorly understood. Using high-resolution shotgun mass spectrometry, we quantified the molar abundance of 316 species from 22 major lipid classes in liver biopsies of 365 patients, including nonsteatotic patients with normal or excessive weight, patients diagnosed with NAFL (nonalcoholic fatty liver) or NASH (nonalcoholic steatohepatitis), and patients bearing common mutations of NAFLD-related protein factors. We confirmed the progressive accumulation of di- and triacylglycerols and cholesteryl esters in the liver of NAFL and NASH patients, while the bulk composition of glycerophospho- and sphingolipids remained unchanged. Further stratification by biclustering analysis identified sphingomyelin species comprising n24:2 fatty acid moieties as membrane lipid markers of NAFLD. Normalized relative abundance of sphingomyelins SM 43:3;2 and SM 43:1;2 containing n24:2 and n24:0 fatty acid moieties, respectively, showed opposite trends during NAFLD progression and distinguished NAFL and NASH lipidomes from the lipidome of nonsteatotic livers. Together with several glycerophospholipids containing a C22:6 fatty acid moiety, these lipids serve as markers of early and advanced stages of NAFL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.